van Hooff M, de Veer R, Karam V, Adam R, Taimr P, Polak W
JHEP Rep. 2024; 6(8):101100.
PMID: 39045337
PMC: 11263784.
DOI: 10.1016/j.jhepr.2024.101100.
Mehtani R, Rathi S
J Clin Exp Hepatol. 2024; 14(6):101432.
PMID: 38975605
PMC: 11222954.
DOI: 10.1016/j.jceh.2024.101432.
Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J
Hepatol Int. 2024; 18(2):299-383.
PMID: 38416312
DOI: 10.1007/s12072-023-10629-3.
Henson J, King L
Clin Liver Dis. 2023; 28(1):193-207.
PMID: 37945160
PMC: 11033708.
DOI: 10.1016/j.cld.2023.07.009.
Tanaka A
Clin Mol Hepatol. 2020; 27(1):1-21.
PMID: 33264835
PMC: 7820210.
DOI: 10.3350/cmh.2020.0028.
Risk factors for recurrent autoimmune liver diseases after liver transplantation: A meta-analysis.
Chen C, Ke R, Yang F, Cai Q, Liu J, Huang X
Medicine (Baltimore). 2020; 99(20):e20205.
PMID: 32443344
PMC: 7253929.
DOI: 10.1097/MD.0000000000020205.
Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population.
Alomari M, Covut F, Al Momani L, Chadalavada P, Hitawala A, Young M
JGH Open. 2020; 4(2):132-139.
PMID: 32280755
PMC: 7144790.
DOI: 10.1002/jgh3.12223.
Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study.
Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E, Tokushige K
Hepatol Commun. 2018; 1(5):394-405.
PMID: 29404468
PMC: 5721413.
DOI: 10.1002/hep4.1037.
Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.
Patel A, Seetharam A
J Clin Exp Hepatol. 2016; 6(4):311-318.
PMID: 28003721
PMC: 5157913.
DOI: 10.1016/j.jceh.2016.10.001.
Recurrence of autoimmune liver diseases after liver transplantation.
Faisal N, Renner E
World J Hepatol. 2015; 7(29):2896-905.
PMID: 26689244
PMC: 4678376.
DOI: 10.4254/wjh.v7.i29.2896.
Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management.
Mitchell O, Cosar A, Malik M, Gurakar A
Hepatol Int. 2015; 10(1):106-14.
PMID: 26603541
DOI: 10.1007/s12072-015-9685-2.
Liver Transplantation for Patients with Cholestatic Liver Diseases.
Schoning W, Schmeding M, Ulmer F, Andert A, Neumann U
Viszeralmedizin. 2015; 31(3):194-8.
PMID: 26468315
PMC: 4569198.
DOI: 10.1159/000431017.
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.
Edmunds C, Ekong U
Transplantation. 2015; 100(3):515-24.
PMID: 26447505
PMC: 4764021.
DOI: 10.1097/TP.0000000000000922.
Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects.
Cholongitas E, Burroughs A
Auto Immun Highlights. 2015; 3(3):113-8.
PMID: 26000134
PMC: 4389079.
DOI: 10.1007/s13317-012-0040-5.
The Cholangiopathies.
Lazaridis K, LaRusso N
Mayo Clin Proc. 2015; 90(6):791-800.
PMID: 25957621
PMC: 4533104.
DOI: 10.1016/j.mayocp.2015.03.017.
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.
Purohit T, Cappell M
World J Hepatol. 2015; 7(7):926-41.
PMID: 25954476
PMC: 4419097.
DOI: 10.4254/wjh.v7.i7.926.
Primary biliary cirrhosis and liver transplantation.
Akamatsu N, Sugawara Y
Intractable Rare Dis Res. 2014; 1(2):66-80.
PMID: 25343075
PMC: 4204562.
DOI: 10.5582/irdr.2012.v1.2.66.
Treatment of autoimmune liver disease: current and future therapeutic options.
Trivedi P, Hirschfield G
Ther Adv Chronic Dis. 2013; 4(3):119-41.
PMID: 23634279
PMC: 3629750.
DOI: 10.1177/2040622313478646.
Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis?.
Wasilenko S, Montano-Loza A, Mason A
Viruses. 2013; 5(2):423-38.
PMID: 23348060
PMC: 3640509.
DOI: 10.3390/v5020423.
Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?.
Smyk D, Rigopoulou E, Zen Y, Abeles R, Billinis C, Pares A
World J Gastroenterol. 2012; 18(35):4855-65.
PMID: 23002357
PMC: 3447267.
DOI: 10.3748/wjg.v18.i35.4855.